Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:B6ZGS9 (
Farnesoid X receptor
)
212
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Farnesoid X receptor
(
FXR
), a ligand-activated transcription factor and a member of nuclear receptor family, is not only highly expressed in the adrenal cortex, intestine, kidney and liver, but also has recently been found in the vasculature. However, the evidence on the roles of
FXR
in the vasculature is limited and whether
FXR
regulates vascular reactivity is poorly understood. In present study, we investigated the expression of
FXR
protein in rat vasculature by immunohistochemical method and tested the effects of
FXR
activation by chenodeoxycholic acid (CDCA) on thoracic aortic contraction and dilation. We also detected the level of nitrite/nitrate (NOx) and superoxide in the thoracic aortic segments. We found that
FXR
was expressed in rat carotid arteries, thoracic aorta, abdominal aorta and femoral arteries.
FXR
activation by CDCA significantly (P<0.01) inhibited the contractile responses of rat thoracic aorta rings to KCl and phenylephrine. The cumulative concentrations of CDCA caused a concentration-dependent relaxation, which could be partly impaired by L-
NAME
, an inhibitor of nitric oxide (NO) synthase. The NOx content in thoracic aorta significantly (P<0.01) increased when treated with CDCA. Meanwhile, the vascular redox status was not altered by high concentration of CDCA. The present study suggested that
FXR
regulated vascular reactivity through NO mechanism, which merits further attention.
...
PMID:Farnesoid X receptor regulates vascular reactivity through nitric oxide mechanism. 2307 85